Marijuana for parkinsonian tremor.

  title={Marijuana for parkinsonian tremor.},
  author={J. P. Frankel and Andrew J. Hughes and Andrew John Lees and Gerald M. Stern},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
In the late nineteenth century cannabis was often prescribed for Parkinsonian tremor, apparently with benefit.' Marijuana is known to contain' several active substances with multiple properties and these include psychotropic, hypnotic, tranquillising, antiemetic, anticonvulsant and analgesic actions. The most potent constituent is thought to be tetrahydrocannabinol (THC) and its hedonic properties have long been exploited for recreational purposes. One of our patients whose severe Parkinsonian… 
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics
Clinical research is reviewed using various formulations of cannabis (botanical products, oral preparations containing ∆9-tetrahydrocannabinol and/or cannabidiol) and currently available preparations in the USA (nabilone and dronabinol), expanded from a recent systematic review to include case reports and case series and results of anonymous surveys of patients using cannabis outside of medical settings.
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?
This review focuses on possible effects of cannabinoid-based medicines, in particular on Parkinsonian and multiple sclerosis-related tremors and the common probable molecular mechanisms.
Cannabis therapy in neurological disorders: Recent advances and perspectives
Although there are clinical studies supporting the use of cannabis preparations as adjuvant therapy in neurological disorders, more investigations are needed to assess their safety and efficacy.
Cannabinoids in Clinical Practice
Cannabis is frequently used by patients with multiple sclerosis for muscle spasm and pain, and in an experimental model of MS low doses of cannabinoids alleviated tremor, and an examination of psychiatric hospital admissions found no evidence of psychosis, however, it may exacerbate existing symptoms.
Cannabinoids in the Treatment of Parkinson’s Disease
Experimental and clinical trials studying the effects of cannabinoids in idiopathic Parkinson’s disease are reviewed, finding only one trial found a reduction of levodopa-induced dyskinesia with cannabinoid treatment and the remaining trials showed no effect on Parkinsonian symptoms.
Implication of Cannabinoids in Neurological Diseases
  • A. D. Valle
  • Medicine, Biology
    Cellular and Molecular Neurobiology
  • 2006
Potential therapeutic uses of cannabinoid receptor agonists include the management of spasticity and tremor in multiple sclerosis/spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer, and vasodilation that accompanies advanced cirrhosis.
Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study
The study suggests that cannabis might have a place in the therapeutic armamentarium of PD, with significant improvement of sleep and pain scores and no significant adverse effects of the drug were observed.
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy
The potential for cannabis to enhance the quality of life of Parkinson's patients is explored and the potential of medical marijuana and related compounds in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease.
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis
No compelling evidence was found to recommend the use of cannabis in PD patients, but a potential benefit was identified with respect to alleviation of PD related tremor, anxiety, pain, improvement of sleep quality and quality of life.


A Manual of Diseases of the Nervous System
  • W. Gowers
  • Medicine
    Edinburgh Medical Journal
  • 1887
The present work is a most painstaking attempt to systematize and elucidate the vast mass of facts which have been accumulated during the labours of recent years.
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
It is proposed that the duration of response is primarily determined by levodopa peripheral pharmacokinetics rather than by central pharmacodynamic factors associated with dopamine storage capacity.